Mean change in BMD of the femoral neck · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Mean change in BMD of the lumbar spine · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Total hip BMD · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
Mean change in BMD of the distal radius · postmenopausal women with osteoporosis and CKD stages 3‐4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Death · postmenopausal women with osteoporosis and CKD stages 3‐4
1 finding from 1 review
QoL · postmenopausal women with osteoporosis and CKD stages 3‐4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stuttering frequency (% SS) · children aged six years and younger who stutter
1 finding from 1 review
Stuttering severity · children aged six years and younger who stutter
1 finding from 1 review
Speech efficiency (syllables per second) · children aged six years and younger who stutter
1 finding from 1 review
Communication attitudes · children aged six years and younger who stutter
1 finding from 1 review
Adverse effects · children aged six years and younger who stutter
1 finding from 1 review
Number of responders · IBD patients
IV iron sucrose showed no clear difference in number of responders ‐ active or inactive disease (6 weeks) compared with oral iron sulphate (low certainty).
1 finding from 1 review
Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Number of responders ‐ disease activity not stated (12 weeks) · IBD patients
Oral ferric maltol showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV ferric carboxymaltose (low certainty).
1 finding from 1 review
Serious adverse events (12 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events (12 weeks) compared with IV ferric carboxymaltose (very low certainty).
1 finding from 1 review
Number of responders ‐ mild to moderate disease (12 weeks) · IBD patients
IV ferric carboxymaltose showed no clear difference in number of responders ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Number of responders · IBD patients
IV iron isomaltoside showed no clear difference in number of responders ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (low certainty).
1 finding from 1 review
Serious adverse events ‐ remission or mild disease (8 weeks) · IBD patients
It is very uncertain whether IV iron isomaltoside changes serious adverse events ‐ remission or mild disease (8 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review